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Aims To determine the effects of percutaneous mitral annuloplasty on symptoms, walk distance and left ventricular (LV)
structure and function in patients with mild or moderate secondary mitral regurgitation (SMR).
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Methods
and results
This was a pooled analysis of patients (n = 68) who, despite guideline-directed medical therapy had symptomatic heart
failure (HF) with mild (n = 25) or moderate (n = 43) SMR treated with percutaneous mitral annuloplasty as part of the
TITAN, TITAN II, or REDUCE-FMR trials. Primary outcomes were changes in symptoms, 6-min walk distance, and
quality of life assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) after 1 year. Secondary analyses
included changes in LV structure and function. At 1 year, New York Heart Association class status was maintained
(48%) or improved (46%) in most patients, mean KCCQ scores increased from baseline by 10 units [95% confidence
interval (CI) 3 to17; P < 0.01] and mean 6-min walk test distance increased by 34 m (95% CI 12 to 57; P < 0.01). SMR
grade improved in 25% of patients and was maintained in 58% of patients with changes in mean regurgitant volume
of −7 mL (95% CI −11 to −3; P < 0.001), vena contracta −0.11 cm (95% CI −0.20 to −0.02; P < 0.05), and effective
regurgitant orifice area −0.03 cm2 (95% CI −0.06 to −0.01; P < 0.05). There were non-significant improvements in
LV ejection fraction and volumes. Survival over 1 year was 89% with no difference between mild (96%) and moderate
(86%) SMR (log-rank P = 0.22). Progression-free survival was 70% (82% in mild vs. 63% in moderate SMR; P = 0.16).
Freedom from HF hospitalization was 73% (87% in mild SMR vs. 66% in moderate SMR; P = 0.07).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Among patients with symptomatic HF and mild or moderate SMR on guideline-directed medical therapy, percutaneous
mitral annuloplasty was associated with improvements in symptoms, SMR, a stabilization of LV structure and function,
and high survival rates.
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Graphical Abstract
The adverse effects of untreated mitral regurgitation in patients with heart failure due to reduced ejection fraction and the possible effects with
earlier percutaneous treatment. HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; SMR, secondary mitral regurgitation.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Keywords Carillon • Heart failure • Indirect mitral annuloplasty • Mitral regurgitation • Survival
Introduction
Secondary mitral regurgitation (SMR) in the presence of left ven-
tricular (LV) systolic dysfunction is directly associated with adverse
outcomes, including mortality.1 Even patients with mild SMR have
a higher risk of hospitalization and mortality compared to those
without SMR. However, despite this knowledge and consistent
data that early medical and cardiac implantable electronic device
treatment in heart failure with reduced ejection fraction (HFrEF)
improves outcomes,2 patients with less severe mitral regurgitation
(MR) have thus far received little attention regarding treatment.
There are specific challenges to studying and treating patients
with milder forms of SMR, despite the recognition of increased
risk. From a mechanistic perspective, those with mild SMR have less
room for improvement. Moreover, the lesser degree of ventricular
and atrial remodelling at baseline and slower progression means
that showing improvement or even a stabilization of progression
are both more difficult compared to patients with more severe
SMR. Identifying a modification of disease progression in clinical
trials addressing earlier stages of the disease therefore requires
longer patient follow-up and a larger sample size, although this
can be somewhat compensated for by true blinding. From a
recruitment perspective, there may also be a lack of drive to enrol
those less sick into a device study due to perceived procedural





































.. treating patients with mild SMR is a safe ‘preventative’ strategy
for progressive disease requires a careful assessment of existing
data to identify a population at risk of deterioration in whom any
procedural risk might be more acceptable.
Percutaneous mitral annuloplasty is a novel treatment for SMR
in which a device is placed into the coronary sinus to reduce its
diameter and allow approximation of the mitral valve leaflets3 to
reduce SMR severity. Studies of percutaneous mitral annuloplasty
for SMR are unique since in addition to patients with severe SMR,
they also included patients with milder degrees of SMR. Three
of these studies, TITAN,4 TITAN II5 and REDUCE FMR6 have
follow-up to at least 1 year. The aim of this analysis was to present
a post-hoc pooled analysis of the 1-year outcomes in patients
with mild or moderate SMR treated with percutaneous mitral
annuloplasty.
Methods
This is a pooled analysis of patients with mild or moderate SMR
treated with a percutaneous mitral annuloplasty procedure utilizing the
coronary sinus-based Carillon device (Cardiac Dimensions, Kirkland,
WA, USA) in the TITAN, TITAN II, and REDUCE FMR trials. Ethics
committees at each site approved the protocols of each trial, all
patients provided written informed consent, and study procedures
complied with the Declaration of Helsinki.
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Patient eligibility in these trials specified ongoing symptomatic heart
failure with LV systolic dysfunction, despite guideline-directed medical
therapy. Patients with class 1 indications for cardiac resynchronization
therapy, or with an LV lead in place, were excluded due to the
shared coronary sinus space used by mitral annuloplasty. All three
trials targeted enrolment to patients with grade 2+ to 4+ SMR. In
TITAN and TITAN II the echo core laboratory pre-screened patients
and excluded patients with 1+ SMR. REDUCE FMR was designed as a
pragmatic trial and local investigators decided upon eligibility. Blinded
core echocardiography laboratory analysis was undertaken only at
study end, revealing that several enrolled patients actually had 1+ SMR.
Additional inclusion criteria for all trials were LV enlargement defined
as >5.5 cm LV end-diastolic diameter and reduced ejection fraction
(<40% in TITAN and TITAN II; <50% in REDUCE FMR).
Independent core laboratories read echocardiograms for quantita-
tive parameters blinded to allocation (for REDUCE-FMR) and visit date
(TITAN, TITAN II and REDUCE FMR). MR grading was based upon
American Society of Echocardiography recommendations.7 The proto-
cols and complete eligibility criteria have been published previously.4–6
The pooled dataset included baseline patient characteristics and
secondary, echocardiographic, and vital status results at 1 year of
follow-up. Baseline patient characteristics were summarized with the
mean and standard deviation for continuous outcomes and counts and
percentage for categorical outcomes. Changes in patient outcomes
over 1 year relative to baseline were analysed with paired-samples
t-tests and presented with 95% confidence intervals (CI). Fisher’s exact
test was used for group comparison of categorical outcomes. Survival
and freedom from heart failure hospitalization were analysed using
Kaplan–Meier methods. Treatment success as a binary outcome vari-
able was characterized by progression-free survival, defined as sur-
vival at 1 year without an increase in SMR grade. The association
of baseline patient characteristics and echocardiographic results with
progression-free survival was analysed with univariable logistic regres-
sion and reported as an odds ratio (OR) and 95% CI. Variables that
entered the model at P < 0.10 were included in a multivariable model.
Although this was a post-hoc analysis, we performed significance test-
ing for information using a P < 0.05 to represent statistical significance.
All tests were two-sided. Statistical analyses were performed using
Stata v16 (StataCorp, College Station, TX, USA).
Results
The pooled dataset of the three studies included 68 patients
treated with percutaneous mitral annuloplasty (52 of whom had
been part of REDUCE FMR, 7 had been in TITAN and 9 in TITAN
II). Of these patients, 25 had mild and 43 moderate SMR. This
represented 51% of device-treated patients enrolled in these trials.
The mean patient age was 69± 9 years, 75% were male, and HFrEF
was predominantly of ischaemic aetiology (68%). All patients were
classified as New York Heart Association (NYHA) functional class
II (35%) or III (65%). The mean LV ejection fraction at baseline
was 32± 8% and LV end-diastolic diameter was 6.5 ± 0.8 cm
(Table 1). Table 1 also shows medical therapy at baseline which was
commensurate with guidelines for medical therapy for HFrEF at
the time of studies.
Patients with moderate SMR had confirmatory quantita-
tive echocardiographic evidence of higher regurgitant volume
(P < 0.001), larger vena contracta (P = 0.007), and larger effective




















































































Table 1 Baseline patient characteristics
Characteristic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Demographics
Age (years) 69± 9
Male sex 75% (51/68)
Body mass index (kg/m2) 27± 5
Medical history
Ischaemic aetiology 68% (46/68)
Prior myocardial infarction 50% (34/68)
Atrial fibrillation 46% (31/68)
Diabetes mellitus 26% (18/68)
Patients with a heart failure







6-min walk distance (m) 316± 89
KCCQ (units) 50± 22
Medical therapy
ACE inhibitor/ARB/ARNi 91% (62/68)
Beta-blocker 93% (63/68)
Loop diuretic 94% (64/68)
MRA diuretic agent 66% (45/68)
Left atrial variables
Left atrial volume, mL 94± 41
LV variables
LV ejection fraction (%) 32± 8
LV end-diastolic diameter (cm) 6.5± 0.8
LV end-systolic diameter (cm) 5.5± 0.9
LV end-diastolic volume (mL) 175± 61
LV end-systolic volume (mL) 122± 53
Mitral valve variables
Regurgitant volume (mL) 27±14
Vena contracta (cm) 0.42± 0.14




Values are mean± SD for continuous variables and (n) or percentage (n/N) for
categorical data.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNi,
angiotensin receptor–neprilysin inhibitor; EROA, effective regurgitant orifice
area; KCCQ, Kansas City Cardiomyopathy Questionnaire; LV, left ventricular;
MR, mitral regurgitation; MRA, mineralocorticoid receptor antagonist; NYHA,
New York Heart Association.
SMR also had a lower prevalence of atrial fibrillation (P = 0.03),
worse NYHA scores (P = 0.009), and lower ejection fraction
(P = 0.03) (online supplementary Table S1).
Procedural device-related safety events occurred in two patients.
In one patient, a branch of the circumflex artery was compressed
by the device. The compression was judged to be non-significant at
the time of procedure; however, the patient developed coronary
spasm with electrocardiographic changes 1 day post-procedure.
The patient continued in the study through 1-year follow-up with
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Structural and functional changes over 1 year following implantation. Mean (95% confidence intervals) for (A) regurgitant volume,
(B) left ventricular (LV) end-diastolic volume, (C) LV ejection fraction and (D) LV end-systolic volume at 1, 6 and 12 months after device
implantation.
only one further occurrence of angina judged to be due to coronary
spasm and treated with medical therapy. The other patient with a
safety event had troponin elevation following the procedure, but
without clinical evidence of myocardial infarction, which did not
require intervention.
During the follow-up period, 7 patients died, and 4 withdrew
consent, leaving 57 who returned for the 1-year follow-up visit. As
appropriate for patients in whom optimal medical therapy was a
requirement of enrolment, medical therapy was unchanged dur-
ing follow-up in the majority of patients with only five patients
either discontinuing or adding a drug category. Four patients dis-
continued any class of drug (two stopping their diuretic, one stop-
ping their beta-blocker, and one stopping both beta-blocker and
angiotensin-converting enzyme inhibitor). In one patient, previ-
ously deemed to be intolerant, a beta-blocker was added.
There were statistically significant decreases in regurgitant vol-
ume (−7 mL; 95% CI −11 to −3; P < 0.001) (Figure 1A), vena
contracta (−0.11 cm; 95% CI −0.20 to 0.02; P < 0.05), and EROA
(−0.03 cm2; 95% CI−0.06 to−0.01; P < 0.05). SMR grade improved
in 25% of patients and was maintained in 58% of patients (Table 2).
There was no progression in LV dysfunction; rather a trend to
reverse remodelling and a significant reduction in LV end-systolic
diameter relative to baseline (Table 2).
Functional status by NYHA classification significantly improved





































. significant improvements in both 6-min walk test distance and
Kansas City Cardiomyopathy Questionnaire were also observed as
soon as 1 month post-procedure and were maintained throughout
follow-up (Figure 2 and Table 2). Relative to the mild SMR group,
those with moderate SMR were more likely to experience an
improvement in NYHA status (P < 0.01) and MR grade (P = 0.01)
(online supplementary Table S2). LV structural and secondary
changes are shown in Figure 1B–D.
In the present dataset, survival was not significantly different
between those with mild SMR (95.8%) and moderate SMR (85.6%)
(log-rank P = 0.22) (Figure 3). Progression-free survival (survival
at 1 year without an increase in MR grade), was 70% overall;
82% in those with mild SMR and 63% in those with moder-
ate SMR (P = 0.16). Freedom from heart failure hospitalization
was 73.3% over 1 year with no significant differences between
the mild and moderate SMR groups (86.5% vs. 66.0%; log-rank
P = 0.07).
The number of patients with any heart failure hospitalization
in the 12-month period following device implant was significantly
lower than those experiencing a heart failure hospitalization in the
12 months prior to the procedure (29.4% vs. 51.4%; P = 0.01).
In a univariable logistic regression model, baseline variables
that were associated with better progression-free survival were
lower NYHA class (P = 0.10), lower regurgitant volume (P = 0.02),
and lower EROA (P = 0.02). In the multivariable model, the
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Change in secondary and echocardiographic
parameters with indirect annuloplasty at 1 year vs.
baseline*
Characteristic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinical status
NYHA class −0.5 (−0.7, −0.3)**
Improvement 46% (26/56)
No change 48% (27/56)
Worsening 5% (3/56)
6-min walk distance (m) 34 (12, 57)***
KCCQ (units) 10 (3,17)***
Left atrial variables
Left atrial volume (mL) 1 (−5, 7)
LV variables
LV ejection fraction (%) 1 (−2, 4)
LV end-diastolic diameter (cm) −0.1 (−0.3, 0)
LV end-systolic diameter (cm) −0.2 (−0.4, −0.1)***
LV end-diastolic volume (mL) −6 (−19, 7)
LV end-systolic volume (mL) −5 (−16, 7)
Mitral valve variables
Regurgitant volume (mL) −7 (−11, −3)**
Vena contracta (cm) −0.11 (−0.20, −0.02)*
EROA (cm2) −0.03 (−0.06, −0.01)*
MR grade −0.1 (−0.3, 0.1)
Improvement 25% (13/53)
No change 58% (31/53)
Worsening 17% (9/53)
Values are mean change (95% confidence interval) for continuous variables, or
percentage (n/N) for categorical data.
EROA, effective regurgitant orifice area; KCCQ, Kansas City Cardiomyopathy
Questionnaire; LV, left ventricular; MR; mitral regurgitation; NYHA; New York
Heart Association.
*P < 0.05 for change vs. baseline.
**P < 0.001 for change vs. baseline.
***P < 0.01 for change vs. baseline.
only baseline variable that was independently associated with
progression-free survival was lower baseline EROA, with an OR
of 3.0 (95% CI 1.21 to 7.39, P = 0.02) for each 0.1 cm2 decrease
(Table 3).
Discussion
The present data provide the strongest data to date that, in
patients with HFrEF with mild or moderate SMR, a transcatheter
annular approach can safely reduce SMR and that doing this
improves symptoms, exercise tolerance and quality of life and
might also attenuate LV remodelling. This finding has potential
implications for the large number of patients with less severe
SMR that are currently not eligible for percutaneous leaflet clip-
ping. Whether these improvements in surrogate endpoints trans-
late to long-term modification of disease progression requires
further work including larger studies and longer follow-up given
the background that many other treatments for HFrEF, when





















































































Figure 2 Health outcomes measures over 1 year following
implantation of the Carillon device in patients with mitral regur-
gitation grade 1 or 2. (A) Distribution of New York Heart Asso-
ciation (NYHA) class during follow-up at baseline and 1 year
(P < 0.001 for change between baseline and 1 year). (B) Kansas
City Cardiomyopathy Questionnaire (KCCQ) values at baseline
and during follow-up. (C) Six-minute walk distance values at base-
line and during follow-up.
The current data complement the results of previous studies
demonstrating improvements in echocardiographic and clinical out-
comes following percutaneous mitral annuloplasty in patients with,
on average, moderate to severe SMR. However, SMR is associated
with worse outcomes even when mild.1 Furthermore, the devel-
opment of SMR is part of a vicious cycle, whereby SMR leads to fur-
ther LV dilatation, which in turn results in worsening SMR. Arrest-
ing this cycle early on may interrupt a key component of cardiac
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 3 Survival over 1 year with the Carillon device in patients with mitral regurgitation (MR) grade 1 or 2. The survival rate at 1 year was
89.3% [standard error (SE) 3.8%] among all patients and 95.8% (SE 4.1%) vs. 85.6% (SE 5.4%) comparing MR grades 1 vs. 2 (log-rank P = 0.22).
Table 3 Association of baseline characteristics with progression-free survival at 1 year
Variable Unit of measure Odds ratio 95% CI P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Univariable analysis
Age Per 5-year decrease 1.24 0.87, 1.76 0.24
Sex Female vs. male 1.24 0.34, 4.59 0.75
Body mass index (kg/m2) Per 5 kg/m2 increase 1.23 0.71, 2.11 0.46
Medical history
Ischaemic aetiology No vs. yes 3.08 0.77, 12.3 0.11
Myocardial infarction No vs. yes 2.10 0.68, 6.47 0.20
Atrial fibrillation Yes vs. no 2.20 0.70, 6.96 0.18
Diabetes mellitus No vs. yes 1.23 0.35, 4.31 0.75
Functional status
NYHA class II vs. III 2.89 0.81, 10.3 0.10
6-min walk distance Per 100 m increase 1.31 0.71, 2.41 0.39
Left atrial variables
Left atrial volume Per 50 mL increase 1.10 0.55, 2.23 0.78
LV variables
LV ejection fraction Per 5% increase 1.33 0.90, 1.95 0.15
LV end-diastolic diameter Per 1 cm decrease 1.31 0.67, 2.59 0.43
LV end-systolic diameter Per 1 cm decrease 1.28 0.70, 2.35 0.41
LV end-diastolic volume Per 50 mL decrease 1.36 0.81, 2.29 0.24
LV end-systolic volume Per 50 mL decrease 1.56 0.85, 2.84 0.15
Mitral valve variables
Regurgitant volume Per 10 mL decrease 1.84 1.12, 3.02 0.02
Vena contracta Per 0.1 cm increase 1.04 0.65, 1.66 0.87
EROA Per 0.1 cm2 decrease 3.00 1.21, 7.39 0.02
MR grade 1 vs. 2 2.62 0.74, 9.33 0.14
Multivariable analysis
EROA Per 0.1 cm2 decrease 3.00 1.21, 7.39 0.02
CI, confidence interval; EROA, effective regurgitant orifice area; LV, left ventricular; MR, mitral regurgitation; NYHA, New York Heart Association.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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deterioration in patients with cardiomyopathy and may play a major
role in stabilization of the disease process. Current guidelines,
based upon the available evidence, focus on patients with severe
SMR stating that mitral valve repair or replacement may be consid-
ered for severely symptomatic patients.8 Due to lacking data, there
is little discussion regarding the potential for disease modification
and the prevention of progression in patients with lesser degrees
of SMR, despite the worse prognosis compared to patients with
no SMR. Whether a diagnosis of mild or moderate MR warrants
transcatheter or surgical treatment is a topic of debate. What is
clear is that early medical and cardiac implantable electronic device
treatments demonstrate accumulating benefits over time, princi-
pally in a slowing of progression in patients when treated early,9–14
which suggests that early treatment for SMR deserves careful study
as well. A key question is to identify those patients in whom SMR is
likely to contribute to longer-term deterioration. This will require
carefully collected large longitudinal observational datasets, as well
as evidence that early treatment is feasible, safe, and delays deterio-
ration. This is therefore the first dataset to explore this hypothesis
of the potential benefits of targeted early treatment prior to clinical
deterioration.
Our analysis suggests that percutaneous mitral annuloplasty in
patients with mild or moderate MR is feasible and safe. After
12 months of follow-up, there were improvements in NYHA class
and 6-min walk distance, and quality of life. There were also
reductions in MR as evidenced by changes in regurgitant volume,
vena contracta, and EROA. As anticipated, the magnitude of these
changes was less in those with mild vs. moderate SMR but, judg-
ing by the concurrent improvements in patient-oriented endpoints,
seem nonetheless clinically significant. Given the modest improve-
ments in MR yet equivalent improvements in clinical variables com-
pared to previous datasets, it is possible that especially in this pop-
ulation the device limits exercise-induced worsening of MR. These
results suggest that percutaneous mitral annuloplasty may be an
effective treatment to provide symptomatic relief in even mild or
moderate MR. These data, including the presented survival data,
may be used for hypothesis generation in the design and statistical
powering of future studies.
The challenge with any treatment for HFrEF is the balance of the
risks of interventions to reduce SMR with the risks of untreated
SMR over the patient’s lifetime. The advent of percutaneous treat-
ments with lower upfront risk, has facilitated explorations of the
potential lifetime benefits of earlier treatment. Future study designs
need to consider the lower event rate in patients with lesser
degrees of SMR and the need therefore for high levels of safety
of the device, larger sample sizes with longer follow-up, and true
blinding. The definitive studies will also need to focus on clinical
outcomes consequent to disease progression rather than improve-
ments of surrogate endpoints.
Limitations
This is the first study to describe the outcomes of patients with
mild or moderate MR treated with a device to reduce SMR.
There are, however, several limitations beyond the uncontrolled,



















































































.. data collected at 1 year of follow-up and extended follow-up is
needed to characterize the long-term safety and effectiveness of
this treatment approach in patients with less severe SMR. Sec-
ond, comparisons of these results to those with other thera-
pies in patients with mild or moderate MR should be made cau-
tiously owing to possible differences in indications, patient char-
acteristics, and echocardiographic protocols. Third, the sample
size in each group was small such that the results should be
considered primarily as hypothesis-generating for planning future
prospective controlled studies. Fourth, of the included studies,
only the randomized, sham-controlled REDUCE FMR study had
an untreated (control) arm including 18 patients fulfilling the cri-
teria for inclusion in this post-hoc analysis. An exploratory anal-
ysis of outcomes in this group described survival at 1 year of
80.8% compared with a 1-year survival of 89.3% in those allo-
cated the device (data not shown). Such a survival analysis is
only hypothesis stimulating but could help power future stud-
ies in this group. Fifth, given the pragmatic design of the studies
and their focus on structural changes and patient-oriented out-
comes, we did not routinely measure plasma-based biomarkers.
Finally, MR assessment was undertaken at rest. Stress echocardio-
graphy was not performed during these studies. Future studies in
those with milder forms of MR could explore whether patients
with stress-induced worsening of MR have a greater gain from
intervention than those in whom mild MR does not deteriorate
with stress.
Conclusions
Among patients with HFrEF and mild or moderate SMR who were
symptomatic despite guideline-directed medical therapy, and would
not be indicated for currently approved percutaneous treatments,
percutaneous mitral annuloplasty is associated with few complica-
tions, and could lead to improvements in clinical status and SMR
parameters, and a stabilization of LV remodelling.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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